USC Trial Finds 2,000-mg DHA Fails to Slow Brain Atrophy or Lift Cognition
Updated
Updated · WIRED · Jul 5
USC Trial Finds 2,000-mg DHA Fails to Slow Brain Atrophy or Lift Cognition
3 articles · Updated · WIRED · Jul 5
Summary
A 24-month randomized trial in 365 adults aged 55 to 80 found high-dose DHA supplements did not improve memory or overall cognitive scores and did not preserve hippocampal volume versus placebo.
DHA still reached the brain: cerebrospinal-fluid levels rose 17% after six months in the supplement group, with similar uptake in participants with and without the APOE ε4 Alzheimer's risk gene.
Researchers said the null result may reflect disrupted DHA metabolism in the brain, inflammation tied to obesity and hypertension, and limited decline in a relatively young cohort with an average age of 66.
The study's interpretation was also constrained by a 38% dropout rate during the Covid-19 pandemic and its single-center design, while the team shifts to biomarker-driven and personalized follow-up studies.
If high-dose fish oil fails, what is the new key to protecting your aging brain?
Is your daily fish oil supplement actually accelerating cognitive decline?
2026 Study Finds No Cognitive Benefit from High-Dose Fish Oil in Alzheimer’s Risk: Rethinking Omega-3 Supplementation
Overview
A major clinical trial led by Keck Medicine of USC, published in June 2026, has challenged the long-standing belief that fish oil supplements boost brain health. Despite years of promotion for omega-3s as a remedy for cognitive decline, the study—supported by leading health organizations—found that high-dose fish oil does not improve cognition in older adults at risk for Alzheimer’s disease. This rigorous research suggests that the benefits of fish oil supplements have been overstated, prompting a re-evaluation of their role in brain health and highlighting the need for decisions based on strong scientific evidence.